Clinical trials: Zoledronic acid
Malignant Neoplasm, Musculoskeletal Complications
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
This randomized clinical trial studies genetics in predicting risk of bisphosphonate-related osteonecrosis of the jaw in patients with cancer receiving zoledronic acid.
- Trial name
- NCT02069340
- Testing
- zoledronic acid, pharmacological study
- Where
- 2 sites in United States
- Sponsor
- University of Southern California
Breast Cancer, Hypercalcemia of Malignancy
Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
RATIONALE: Zoledronic acid may help decrease the risk of broken bones, bone pain, and other symptoms caused by bone metastases. It may also help patients live more comfortably.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Musculoskeletal Complications
- Trial name
- NCT00458796
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 30 sites in United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- University of Leeds
Osteoporosis
The Optimised Use of Romozosumab Study
OPTIMIST is a two-year, randomised, active controlled, open-label, multicentre intervention trial. OPTIMIST includes 3 treatment groups each comprising combinations of romosozumab (ROMO) and zoledronate (ZOL) treatment used in…
- Trial name
- OPTIMIST (NCT06059222)
- Testing
- Romosozumab, Zoledronate
- Where
- Denmark
- Volunteers
- 270 people
- Sponsor
- University of Aarhus
Breast Cancer
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only.
- Trial name
- HOBOE (NCT00412022)
- Testing
- tamoxifen, triptorelin, letrozole
- Where
- 20 sites in Italy
- Volunteers
- 1,294 people
- Sponsor
- National Cancer Institute, Naples
Prostate Cancer
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
To assess the effects of i.v. zoledronic acid 4 mg with respect to safety and tolerability
- Trial name
- NCT00242554
- Testing
- Zoledronic acid
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
- Trial name
- EURODEC (NCT05575167)
- Testing
- Zoledronate or Alendronate
- Where
- 9 sites in France, Greece and 1 more
- Volunteers
- 122 people
- Sponsor
- 424 General Military Hospital
Breast Cancer
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after…
- Trial name
- NATAN (NCT00512993)
- Testing
- Zoledronic acid
- Where
- 93 sites in Austria, Germany
- Volunteers
- 654 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone…
- Trial name
- NCT00375505
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer, Renal Cell Carcinoma
Zoledronate With Atorvastatin in Renal Cell Carcinoma
Objectives: Primary: Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy Secondary: 1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases…
- Trial name
- NCT00490698
- Testing
- Zoledronate, Atorvastatin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
The aim of this study is to evaluate the effect of bortezomib in combination with dexamethasone and zoledronic acid on bone mineral density (BMD) and skeletal related events (SREs) in Patients with Multiple Myeloma who Have…
- Trial name
- NCT00972959
- Testing
- Bortezomib, Zoledronic Acid, Dexamethasone
- Where
- 3 sites in Greece
- Volunteers
- 17 people
- Sponsor
- University of Athens
Prostate Cancer Patients With Bone Metastasis
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
- Trial name
- NCT00237159
- Testing
- Zoledronic acid
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Trochanteric Fracture of Femur
Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate
The purpose of this study is to study the process of bone regeneration around a metal device in the femoral neck canal using a synthetic bone substitute Cerament bone void filler (BVF) and bisphosphonate (Zometa) locally or…
- Trial name
- NCT04498715
- Testing
- OSTEOSYNTHESIS, Zoledronic Acid, CERAMENT BONE VOID FILLER (BVF)
- Where
- Lithuania
- Volunteers
- 20 people
- Sponsor
- Lithuanian University of Health Sciences
Breast Cancer, Stage IV Breast Cancer
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group)…
- Conditions
- Breast Cancer, Stage IV Breast Cancer, Bone Metastases
- Trial name
- POSITIVE-Bone (NCT07687225)
- Testing
- Primary Tumor Resection, Standard systemic therapy
- Volunteers
- 216 people
- Sponsor
- West China Hospital
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Osteoporosis
The Optimal Sequential Therapy After Long Term Denosumab Treatment
This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.
- Trial name
- NCT05091099
- Testing
- zoledronate, Alendronate and Zoledronate
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- National Taiwan University Hospital
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Osteoporosis
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine…
- Trial name
- NCT00439244
- Testing
- Zoledronic acid, Teriparatide
- Where
- 33 sites in United States, Belgium and 2 more
- Volunteers
- 412 people
- Sponsor
- Novartis
Primary Hyperparathyroidism
Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism
This study is a randomized, double-blinded, placebo-controlled trial investigating the effects of zoledronic acid (ZOL) versus placebo in patients with primary hyperparathyroidism (PHPT) undergoing parathyroidectomy (PTX).
- Trial name
- ZOLPHPT (NCT06859580)
- Testing
- Zoledronic acid 4 mg, Natriumklorid 9 mg/ml, Fresenius Kabi
- Where
- Denmark
- Volunteers
- 140 people
- Sponsor
- University of Aarhus
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Solitary Osseous Plasmacytoma
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well they work when given after radiation therapy in treating patients with solitary…
- Trial name
- NCT02516423
- Testing
- ixazomib, lenalidomide, dexamethasone
- Where
- 388 sites in United States
- Volunteers
- 11 people
- Sponsor
- Alliance for Clinical Trials in Oncology